



PRESS RELEASE

10 March 2022

Recipharm pledges support to conflict victims

Recipharm, the global contract development and manufacturing organisation (CDMO), has today announced its commitment to helping victims of the conflict in Ukraine. The company is taking steps to provide support to those of its own employees who are directly impacted and to launch a fundraising campaign in which it will match the financial contributions of its staff.

CEO Marc Funk said: "Given the unprovoked invasion of Ukraine and the tragic humanitarian crisis which is now unfolding, we believe it is important to offer our help wherever it can be most effective. We at Recipharm are working with NGO partners to provide urgent aid and other humanitarian assistance to refugees. Our employees are keen to engage with this issue and to lend their support where they can, so we are setting up a matched funding arrangement to facilitate the donation process, working in conjunction with UNICEF, our chosen partner."

For further information, please contact:

Marcus Smith, Head of Communications at Recipharm, marcus.smith@recipharm.com

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit www.recipharm.com